Carlos Diego Ferreira notified for potential USADA violation, out of bout with Trujillo

Carlos Diego Ferreira has been notified of a potential violation of the Anti-Doping Policy.


Ferreira was flagged last week for the potential violation after failing a random out-of-competition drug test administered by USADA, the UFC announced. He was subsequently given a provisional suspension and was pulled from his upcoming bout at UFC Fight Night 88 against Abel Trujillo. A replacement opponent for Trujillo has not yet been found.


The UFC released a statement regarding the possible violation which can be read below.

"The UFC organization was notified today that the U.S. Anti-Doping Agency (USADA) informed Carlos Diego Ferreira of a potential Anti-Doping Policy violation, stemming from a recent out-of-competition sample collection. In accordance with the UFC Anti-Doping Policy, Ferreira has received a provisional suspension, and has been removed from his scheduled bout against Abel Trujillo on May 29 in Las Vegas.

USADA, the independent administrator of the UFC Anti-Doping Policy, will handle the results management and appropriate adjudication of this case. It is important to note that, under the UFC Anti-Doping Policy, there is a full and fair review process that is afforded to all athletes before any sanctions are imposed.

UFC will announce a replacement opponent for Trujillo shortly, while additional violation information will be provided at the appropriate time as the process moves forward."


Ferreira (12-2) is 1-2 in his past three bouts. His undefeated record was broken by Beneil Dariush at UFC 179 last year which was followed by a knockout loss to Dustin Poirier two months later. He is coming off of a unanimous decision victory over Olivier Aubin-Mercier at UFC on FOX 18.


Jamal Khayat is a writer for RoughCopy MMA. He began his training in combat sports in 2009 and has competed as an amateur in both MMA and boxing. He is currently pursuing a B.S. degree in Physics at the University of Central Florida.


  • No comments

Leave a comment

You must be logged in to leave comments.